Besivance (besifloxacin ophthalmic suspension) 0.6%


BESIVANCE (besifloxacin ophthalmic suspension) 0.6%, is a quinolone antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria:

Aerococcus viridans *, CDC coryneform group G, Corynebacterium pseudodiphtheriticum*, Corynebacterium striatum*, Haemophilus influenzae, Moraxella catarrhalis*, Moraxella lacunata*, Pseudomonas  aeruginosa *, Staphylococcus aureus, Staphylococcus  epidermidis, Staphylococcus hominis*, Staphylococcus  lugdunensis*, Staphylococcus warneri*,  Streptococcus mitis  group, Streptococcus oralis, Streptococcus pneumoniae, Streptococcus salivarius*
*Efficacy for this organism was studied in fewer than 10 infections.

Important Safety Information

  • Besivance is for topical ophthalmic use only, and should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye.
  • As with other anti-infectives, prolonged use of Besivance may result in overgrowth of nonsusceptible organisms, including fungi. If super-infection occurs, discontinue use and institute alternative therapy. 
  • Patients should not wear contact lenses if they have signs or symptoms of bacterial conjunctivitis or during the course of therapy with Besivance.
  • The most common adverse event reported in 2% of patients treated with Besivance was conjuntival redness. Other adverse events reported in patients receiving Besivance occuring in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache.
  • Besivance is not intended to be administered systemically. Quinolones administered systemically have been associated with hypersensitivity reactions, even following a single dose. Patients should be advised to discontinue use immediately and contact their physician at the first sign of a rash or allergic reaction. 
  • Safety and effectiveness in infants below one year of age have not been established.

Please click here (214.8 KB, PDF)to view the Besivance full Prescribing Information.

1. Besivance Prescribing Information. September 2012.